Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: BioRad, Nanosphere

Premium

BioRad Laboratories stockholders have re-elected Louis Drapeau and Albert Hillman as class A directors, and Deborah Neff, Alice Schwartz, and Norman Schwartz as class B directors.


Nanosphere announced the appointment of Ken Bahk as its chief strategy officer, a new position, and that CTO Tim Patno and board member Chad Mirkin will be leaving the company.

Bahk was part of Nanosphere's initial team, and served with the company until 2008. In his new role at Nanosphere, he will be responsible for driving strategic plans and revenues in molecular diagnostics.

He is currently a director of investments at Lurie Investments and previously served as the chair of strategic opportunities for the Association for Molecular Pathology.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.